Skip to main content
. 2022 Feb 5;11(3):553. doi: 10.3390/cells11030553

Figure 1.

Figure 1

Proposed pre-transplant management of MF candidates to allogeneic stem cells transplantation. IMIDs: immunomodulating agents; RUX: ruxolitinib; MTD: maximum tolerated dose; RBC: red blood cells; SpR: spleen response; NR: no response; PD: progressive disease.